Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial
© American Association for Clinical Chemistry 2023. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Plasma fatty acids (FAs) have been associated with cardiovascular disease (CVD) risk. Diet and endogenous metabolism influence the FA profile of the plasma phospholipid (PL) fraction. In the PREDIMED trial, we examined 1-year changes in the FA profile of plasma PL according to a nutritional intervention with Mediterranean diets, either supplemented with extra-virgin olive oil (MedDiet + EVOO) or mixed nuts (MedDiet + nuts), in a high cardiovascular risk population. We also analyzed if 1-year changes in PL FAs were associated with subsequent cardiovascular risk.
METHODS: We included 779 participants in our case-cohort study: 185 incident cases and 594 participants in the subcohort (including 31 overlapping cases). The end point was the incidence of CVD. We measured the FAs of plasma PL at baseline and after 1 year of intervention.
RESULTS: MedDiet + EVOO increased C17:0 and C20:3n9 in linear regression models [β coefficientperSD : 0.215 (95% CI, 0.032-0.399) and 0.271 (0.107-0.434), respectively] and decreased 16:1n7 and C22:4n6 [βperSD: -0.239 (95% CI, -0.416 to -0.061) and -0.287 (95% CI, -0.460 to -0.113), respectively] vs the control group. MedDiet + nuts increased C18:3n3 [βperSD: 0.382 (95% CI, 0.225 - 0.539)], C18:2n6 [βper SD: 0.250 (95% CI, 0.073 - 0.428)], C18:0 [βperSD: 0.268 (95% CI, 0.085-0.452)], and C22:0 [βper SD: 0.216 (95% CI, 0.031-0.402)]; and decreased the sum of six n6 FAs [βper SD: -0.147 (95% CI, -0.268 to -0.027)] vs the control group. The 1-year increase in C18:2n6 was inversely associated with the subsequent CVD risk (HRperSD: 0.64 (95% CI, 0.44-0.92)).
CONCLUSIONS: MedDiet interventions changed n6 FAs and C16:1n7c; other changes were specific for each group: MedDiet + EVOO increased C17:0 and C20:3n9, and MedDiet + Nuts C18:3n3, C18:2n6, C18:0, and C22:0 FAs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Clinical chemistry - 69(2023), 3 vom: 01. März, Seite 283-294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Razquin, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular risk |
|---|
| Anmerkungen: |
Date Completed 03.03.2023 Date Revised 21.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/clinchem/hvac221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351941746 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351941746 | ||
| 003 | DE-627 | ||
| 005 | 20231226052609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/clinchem/hvac221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351941746 | ||
| 035 | |a (NLM)36683466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Razquin, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Supplemented Mediterranean Diets on Plasma-Phospholipid Fatty Acid Profiles and Risk of Cardiovascular Disease after 1 Year of Intervention in the PREDIMED Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2023 | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © American Association for Clinical Chemistry 2023. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Plasma fatty acids (FAs) have been associated with cardiovascular disease (CVD) risk. Diet and endogenous metabolism influence the FA profile of the plasma phospholipid (PL) fraction. In the PREDIMED trial, we examined 1-year changes in the FA profile of plasma PL according to a nutritional intervention with Mediterranean diets, either supplemented with extra-virgin olive oil (MedDiet + EVOO) or mixed nuts (MedDiet + nuts), in a high cardiovascular risk population. We also analyzed if 1-year changes in PL FAs were associated with subsequent cardiovascular risk | ||
| 520 | |a METHODS: We included 779 participants in our case-cohort study: 185 incident cases and 594 participants in the subcohort (including 31 overlapping cases). The end point was the incidence of CVD. We measured the FAs of plasma PL at baseline and after 1 year of intervention | ||
| 520 | |a RESULTS: MedDiet + EVOO increased C17:0 and C20:3n9 in linear regression models [β coefficientperSD : 0.215 (95% CI, 0.032-0.399) and 0.271 (0.107-0.434), respectively] and decreased 16:1n7 and C22:4n6 [βperSD: -0.239 (95% CI, -0.416 to -0.061) and -0.287 (95% CI, -0.460 to -0.113), respectively] vs the control group. MedDiet + nuts increased C18:3n3 [βperSD: 0.382 (95% CI, 0.225 - 0.539)], C18:2n6 [βper SD: 0.250 (95% CI, 0.073 - 0.428)], C18:0 [βperSD: 0.268 (95% CI, 0.085-0.452)], and C22:0 [βper SD: 0.216 (95% CI, 0.031-0.402)]; and decreased the sum of six n6 FAs [βper SD: -0.147 (95% CI, -0.268 to -0.027)] vs the control group. The 1-year increase in C18:2n6 was inversely associated with the subsequent CVD risk (HRperSD: 0.64 (95% CI, 0.44-0.92)) | ||
| 520 | |a CONCLUSIONS: MedDiet interventions changed n6 FAs and C16:1n7c; other changes were specific for each group: MedDiet + EVOO increased C17:0 and C20:3n9, and MedDiet + Nuts C18:3n3, C18:2n6, C18:0, and C22:0 FAs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Mediterranean diet | |
| 650 | 4 | |a PREDIMED | |
| 650 | 4 | |a cardiovascular risk | |
| 650 | 4 | |a fatty acids | |
| 650 | 4 | |a phospholipid fraction | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a Phospholipids |2 NLM | |
| 700 | 1 | |a Ruiz-Canela, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Wernitz, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Toledo, Estefania |e verfasserin |4 aut | |
| 700 | 1 | |a Corella, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Gómez, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Fitó, Montse |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Gracia, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Estruch, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Fiol, Miquel |e verfasserin |4 aut | |
| 700 | 1 | |a Lapetra, José |e verfasserin |4 aut | |
| 700 | 1 | |a Serra-Majem, Lluis |e verfasserin |4 aut | |
| 700 | 1 | |a Ros, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Arós, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Salas-Salvadó, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze, Matthias B |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Gonzalez, Miguel A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry |d 1955 |g 69(2023), 3 vom: 01. März, Seite 283-294 |w (DE-627)NLM000002003 |x 1530-8561 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:283-294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/clinchem/hvac221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2023 |e 3 |b 01 |c 03 |h 283-294 | ||